High Dose Ascorbic Acid Treatment of CMT1A

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Charcot-Marie-Tooth Disease, Type Ia
Interventions
DRUG

Ascorbic acid (Vitamin C)

Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).

DRUG

placebo

Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.

Trial Locations (3)

14642

University of Rochester Medical Center, Dept of Neurology, Rochester

21287

Johns Hopkins University, Dept of Neurology, Baltimore

48201

Wayne State University, Dept of Neurology, Detroit

All Listed Sponsors
collaborator

Muscular Dystrophy Association

OTHER

collaborator

Charcot-Marie-Tooth Association

OTHER

lead

Wayne State University

OTHER

NCT00484510 - High Dose Ascorbic Acid Treatment of CMT1A | Biotech Hunter | Biotech Hunter